Skip to main content

Publications

featured publications

  • Elotuzumab spares dendritic cell integrity and functionality.

    Journal of cancer research and clinical oncology

    Authors: Sebastian Schlaweck, Leon Strauss, Solveig Daecke, Peter Brossart, Annkristin Heine

  • G-quadruplexes: a promising target for cancer therapy.

    Molecular cancer

    Authors: Nils Kosiol, Stefan Juranek, Peter Brossart, Annkristin Heine, Katrin Paeschke

  • Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah's Witness patient.

    Annals of hematology

    Authors: Sebastian Schlaweck, Peter Brossart, Annkristin Heine

  • Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.

    Blood cancer journal

    Authors: Marc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, Uta Bertsch, Hans J Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S Raab, Jens Hillengaß, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W Blau, Christof Scheid, Britta Besemer, Katja C Weisel, Mathias Hänel, Jan Dürig, Hartmut Goldschmidt

  • CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).

    Cancer immunology, immunotherapy : CII

    Authors: Simon Fietz, Romina Zarbl, Dennis Niebel, Christian Posch, Peter Brossart, Gerrit H Gielen, Sebastian Strieth, Torsten Pietsch, Glen Kristiansen, Friedrich Bootz, Jennifer Landsberg, Dimo Dietrich

  • Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.

    EBioMedicine

    Authors: Anne Fröhlich, Judith Sirokay, Simon Fietz, Timo J Vogt, Jörn Dietrich, Romina Zarbl, Mike Florin, Pia Kuster, Gonzalo Saavedra, Susana Ramírez Valladolid, Friederike Hoffmann, Lukas Flatz, Sandra S Ring, Carsten Golletz, Torsten Pietsch, Sebastian Strieth, Peter Brossart, Gerrit H Gielen, Glen Kristiansen, Friedrich Bootz, Jennifer Landsberg, Dimo Dietrich

  • Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

    Leukemia

    Authors: Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, Natalia Becker, Christina Habermehl, Thomas Hielscher, Marc-Steffen Raab, Jens Hillengass, Sandra Sauer, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Dirk Hose, Anja Seckinger, Peter Brossart, Martin Goerner, Stefan Klein, Martin Schmidt-Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Hans Martin, Hans W Lindemann, Christoph Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel

  • Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.

    Leukemia

    Authors: Elias K Mai, Kaya Miah, Uta Bertsch, Jan Dürig, Christof Scheid, Katja C Weisel, Christina Kunz, Markus Munder, Hans-Walter Lindemann, Maximilian Merz, Dirk Hose, Anna Jauch, Anja Seckinger, Steffen Luntz, Sandra Sauer, Stephan Fuhrmann, Peter Brossart, Ahmet Elmaagacli, Martin Goerner, Helga Bernhard, Martin Hoffmann, Marc S Raab, Igor W Blau, Mathias Hänel, Axel Benner, Hans J Salwender, Hartmut Goldschmidt

  • Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses.

    Cancer immunology, immunotherapy : CII

    Authors: Niklas Remke, Savita Bisht, Sebastian Oberbeck, Jens Nolting, Peter Brossart